Life Sciences & Medicine Active Updated Aug 1, 2026
Researchers are attacking Alzheimer's from several directions at once: the biology of how it spreads, drugs that reprogram the brain's immune cells, and blood tests that could catch it years early.
Aug 1, 2026 Latest
New Scientist reported that thousands of people in China have received a lymphatic drainage surgery for Alzheimer's that remains banned in most countries, after small safety trials in the US and Singapore found it safe for up to six months with some signs of cognitive improvement, and a randomized trial against a sham procedure is now underway to test whether it actually works.
Jul 27, 2026
A VIB, KU Leuven, UK Dementia Research Institute and Muna Therapeutics team, publishing in Nature Medicine, compared brain tissue from people with dementia, cognitively healthy older adults, and cognitively healthy centenarians and found some centenarian brains carried heavy amyloid and tau pathology without memory loss. Co-senior author Bart De Strooper's team traced the difference to microglia shifting into distinct protective states in the resistant brains.
Jul 25, 2026
Buck Institute researchers led by Lisa Ellerby engineered human stem cell-derived neurons differing only in APOE genotype and found APOE2 neurons accumulated less DNA damage, switched on DNA repair pathways more strongly, and resisted cellular senescence, with aged mice carrying the human APOE2 gene showing the same pattern in hippocampal tissue.
Jul 21, 2026
A University of Kentucky team led by Shannon Macauley and Nicholas Constantino found that in mice with amyloid plaques, sleep loss traces not to the plaques themselves but to microglia triggering broad brain inflammation while clearing them. Temporarily depleting the microglia restored more than two hours of deep, slow-wave sleep a day without clearing any plaques.
Jul 19, 2026
KCL-286, a drug already proven safe in human Phase 1 trials for a different condition, repaired DNA damage and cut inflammation in a mouse model of Alzheimer's, targeting the disease at a stage before amyloid plaques even form.
Jul 15, 2026
A study led by Kaley Hayes at the University of Massachusetts found older adults recently discharged from skilled nursing facilities who received the recombinant shingles vaccine Shingrix had a lower rate of new dementia diagnosis over four years, enough to estimate the shot could prevent roughly one in 17 cases. The effect builds on an older, discontinued shingles vaccine that showed the same signal, and on the idea that shingles itself inflames the brain and raises stroke risk.
Jul 11, 2026
A University of Kansas Medical Center study found Alzheimer's patients who took daily creatine for two months showed measurable increases in brain energy levels and cognitive test scores, testing the idea that refueling neurons running low on cellular energy helps alongside existing plaque-targeted treatments.
Jul 8, 2026
A Monash University team treated an Alzheimer's mouse model with a copper compound called Cu(ATSM) for 56 days and found P-glycoprotein pump abundance at the blood-brain barrier rose 24.1 percent, amyloid-beta in the brain dropped 42 percent, and spatial learning improved by nearly 44 percent. The approach targets the brain's own waste-clearance system rather than attacking toxic proteins directly. Cu(ATSM) has already been tested in human clinical trials for Parkinson's disease and ALS, giving it an unusual head start on safety evaluation.
Jul 7, 2026
Mass General Brigham researchers confirmed for the first time in humans that the BCG tuberculosis vaccine can cross the blood-brain barrier into cerebrospinal fluid. In healthy older adults without existing Alzheimer's pathology, BCG shifted amyloid-beta levels downward in cerebrospinal fluid while raising them in the bloodstream, suggesting the vaccine helped push the protein out of the central nervous system. The protective shift was absent in participants who already had established Alzheimer's biomarkers, indicating timing is critical.
Jul 2, 2026
Scientists identified a set of circulating RNA molecules in the blood that flagged Alzheimer's onset two to four years before symptoms appeared.
Jun 30, 2026
A University of Utah team showed Alzheimer's spreads tau using the brain's own transport system via the Arc protein, and that blocking Arc cut the spread by about 99 percent in mice.
Jun 20, 2026
Researchers reported a molecule that reprograms the brain's own immune cells, the microglia, to restore their protective function against Alzheimer's damage.
Jun 18, 2026
A study from Niigata University found that APP, the protein most often blamed for Alzheimer's, also acts as a cellular cleaner that protects neurons, complicating the simple plaque story.
The checkable promises in this story, tracked until they are kept or broken.
Promising Alzheimer's drugs can slow progression when started early, but the infrastructure for population-scale screening does not yet exist.
Reporting in the Today Got Better brief
several promising Alzheimer's drugs have shown they can slow progression when started early, but the clinical infrastructure for population-scale screening does not exist yet
When this arc advances, the timeline above grows the same morning. One short, warm letter with the day's real progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.